Results of ibrutinib for CLL relapse after alloHCT
| Series (study) . | N (% 17p−) . | Age, y . | Time from alloHCT to ibrutinib, mo (range) . | ORR (CR), % . | Grade 3-5 toxicity . | De novo GVHD . | 2-y PFS, % . | 2-y OS, % . | Median follow-up, mo (range) . | Reference . |
|---|---|---|---|---|---|---|---|---|---|---|
| Dresden | 5 (20% 17p−) | 58 (38-63) | 30 (6-38) | 100 (0) | 40% (infection; no fatalities) | 0 | NA | NA | NA | 78 |
| US trial cohort | 16 (63% 17p−) | 55 (43-68) | 27 (8-115) | 88 (13%) | 75% (infection, bleeding; 2 fatalities) | 0 | 77 | NA | NA | 79 |
| Stanford | 11 (36% 17p−) | 59 (41-69) | 55 (43-68) | 91 (64) | 25% (infection, skin; 2 fatalities) | 0 | NA | NA | NA | 79 |
| EBMT | CLL 55 (31% 17p−) | 55 (38-66) | 21 (0.5-81) | 70 (33) | 10% (second neoplasm, skin; no fatalities) | 1 chronic (limited) | 51 | 72 | 14 (3-32) | 80 |
| MCL 5 |
| Series (study) . | N (% 17p−) . | Age, y . | Time from alloHCT to ibrutinib, mo (range) . | ORR (CR), % . | Grade 3-5 toxicity . | De novo GVHD . | 2-y PFS, % . | 2-y OS, % . | Median follow-up, mo (range) . | Reference . |
|---|---|---|---|---|---|---|---|---|---|---|
| Dresden | 5 (20% 17p−) | 58 (38-63) | 30 (6-38) | 100 (0) | 40% (infection; no fatalities) | 0 | NA | NA | NA | 78 |
| US trial cohort | 16 (63% 17p−) | 55 (43-68) | 27 (8-115) | 88 (13%) | 75% (infection, bleeding; 2 fatalities) | 0 | 77 | NA | NA | 79 |
| Stanford | 11 (36% 17p−) | 59 (41-69) | 55 (43-68) | 91 (64) | 25% (infection, skin; 2 fatalities) | 0 | NA | NA | NA | 79 |
| EBMT | CLL 55 (31% 17p−) | 55 (38-66) | 21 (0.5-81) | 70 (33) | 10% (second neoplasm, skin; no fatalities) | 1 chronic (limited) | 51 | 72 | 14 (3-32) | 80 |
| MCL 5 |
MCL, mantle cell lymphoma; NA, not available.